Editorial overview: Respiratory: Pulmonary pharmacology–The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives
MC reports grants and personal fees from Almirall , 10.13039/100001003 Boehringer Ingelheim , 10.13039/100004336 Novartis and Zambon and personal fees from ABC Farmaceutici, AstraZeneca, Biofutura, Chiesi Farmaceutici, Cipla, Edmond Pharma, GlaxoSmithKline, Lallemand, Menarini, Mundipharma, Ockham Biotech, Pfizer, Sanofi and Verona Pharma. MGM reports grants and personal fees from 10.13039/100004330 GlaxoSmithKline and 10.13039/100004336 Novartis and personal fees from ABC Farmaceutici, Boehringer Ingelheim, AstraZeneca and Chiesi Farmaceutici. LC reports grants and personal fees from 10.13039/100001003 Boehringer Ingelheim and 10.13039/100004336 Novartis , grants from 10.13039/100007560 Chiesi Farmaceutici , personal fees from ABC Farmaceutici, Edmond Pharma, Ockham Biotech, Verona Pharma and Zambon, grants from Almirall, and non-financial support from AstraZeneca. PR reports grants and personal fees from Almirall , 10.13039/100001003 Boehringer Ingelheim , 10.13039/100007560 Chiesi Farmaceutici , 10.13039/100004336 Novartis and Zambon and personal fees from AstraZeneca, Biofutura, Edmond Pharma, GlaxoSmithKline and Sanofi. 

